Log in

NASDAQ:OCUL - Ocular Therapeutix Stock Price, Forecast & News

+0.04 (+0.82 %)
(As of 03/30/2020 06:56 AM ET)
Today's Range
Now: $4.92
50-Day Range
MA: $5.23
52-Week Range
Now: $4.92
Volume641,195 shs
Average Volume1.89 million shs
Market Capitalization$258.69 million
P/E RatioN/A
Dividend YieldN/A
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant for the treatment of wet age-related macular degeneration(AMD); and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. Its various preclinical programs include OTX-BPI for the treatment of acute ocular pain; OTX-BSI to treat post-operative Pain, and inflammation and bacterial infection; OTX-KTO for the treatment of allergy; and OTX-CSI to treat chronic dry-eye. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds to address conditions of the eye. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.
Read More
Ocular Therapeutix logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:OCUL



Sales & Book Value

Annual Sales$4.23 million
Book Value($0.08) per share


Net Income$-86,370,000.00
Net Margins-2,043.34%


Market Cap$258.69 million
Next Earnings Date5/8/2020 (Estimated)

Receive OCUL News and Ratings via Email

Sign-up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

How has Ocular Therapeutix's stock been impacted by COVID-19 (Coronavirus)?

Ocular Therapeutix's stock was trading at $5.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OCUL stock has decreased by 8.0% and is now trading at $4.92. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ocular Therapeutix?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ocular Therapeutix.

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Ocular Therapeutix.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix Inc (NASDAQ:OCUL) released its earnings results on Thursday, March, 12th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the Zacks' consensus estimate of ($0.45) by $0.08. The biopharmaceutical company earned $2.26 million during the quarter, compared to the consensus estimate of $2.30 million. Ocular Therapeutix had a negative net margin of 2,043.34% and a negative return on equity of 801.90%. View Ocular Therapeutix's earnings history.

What price target have analysts set for OCUL?

7 Wall Street analysts have issued twelve-month price objectives for Ocular Therapeutix's shares. Their forecasts range from $3.00 to $11.00. On average, they anticipate Ocular Therapeutix's share price to reach $7.00 in the next year. This suggests a possible upside of 42.3% from the stock's current price. View analysts' price targets for Ocular Therapeutix.

Has Ocular Therapeutix been receiving favorable news coverage?

Press coverage about OCUL stock has trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ocular Therapeutix earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutOcular Therapeutix.

Are investors shorting Ocular Therapeutix?

Ocular Therapeutix saw a drop in short interest in February. As of February 14th, there was short interest totaling 6,130,000 shares, a drop of 7.8% from the January 30th total of 6,650,000 shares. Based on an average daily volume of 639,000 shares, the short-interest ratio is currently 9.6 days. Currently, 14.7% of the shares of the company are sold short. View Ocular Therapeutix's Current Options Chain.

Who are some of Ocular Therapeutix's key competitors?

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Celgene (CELG), Omeros (OMER), TG Therapeutics (TGTX), Cara Therapeutics (CARA), Melinta Therapeutics (MLNT), Egalet (EGLT) and NVIDIA (NVDA).

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the following people:
  • Mr. Antony Mattessich, Pres, CEO & Director (Age 52)
  • Mr. Donald Notman Jr., Chief Financial Officer
  • Dr. Michael H. Goldstein, Chief Medical Officer (Age 52)
  • Mr. Kevin F. Hanley, Sr. VP of Technical Operations (Age 57)
  • Dr. Peter K. Jarrett Ph.D., Chief Scientific Officer (Age 62)

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Deltec Asset Management LLC (4.42%), Man Group plc (1.58%), State Street Corp (1.47%), Geode Capital Management LLC (1.19%), Ieq Capital LLC (0.53%) and Ieq Capital LLC (0.53%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein, Opaleye Management Inc, Richard L Md Lindstrom and Summer Road Llc. View institutional ownership trends for Ocular Therapeutix.

Which major investors are selling Ocular Therapeutix stock?

OCUL stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, FMR LLC, Nuveen Asset Management LLC, Nottingham Advisors Inc., Mercer Global Advisors Inc. ADV, Goldman Sachs Group Inc., and Barclays PLC. View insider buying and selling activity for Ocular Therapeutix.

Which major investors are buying Ocular Therapeutix stock?

OCUL stock was purchased by a variety of institutional investors in the last quarter, including Ieq Capital LLC, Ieq Capital LLC, Deltec Asset Management LLC, Levin Capital Strategies L.P., Geode Capital Management LLC, Virtu Financial LLC, State Street Corp, and California Public Employees Retirement System. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein, Opaleye Management Inc, Richard L Md Lindstrom, and Summer Road Llc. View insider buying and selling activity for Ocular Therapeutix.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $4.92.

How big of a company is Ocular Therapeutix?

Ocular Therapeutix has a market capitalization of $258.69 million and generates $4.23 million in revenue each year. The biopharmaceutical company earns $-86,370,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Ocular Therapeutix employs 167 workers across the globe. View additional information about Ocular Therapeutix.

What is Ocular Therapeutix's official website?

The official website for Ocular Therapeutix is http://www.ocutx.com/.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]

MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  367 (Vote Outperform)
Underperform Votes:  248 (Vote Underperform)
Total Votes:  615
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe OCUL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCUL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel